HOPE-B Shows Bleeding Control Still Holding at 5 Years

Five years after treatment, patients in the HOPE-B study largely still enjoy the benefit they obtained from gene therapy for hemophilia B: bleeding reduction with little to no need for factor replacement.

The end-of-study analysis, reported at the…